Vascular endothelial growth factor monoclonal antibodies

Category Monoclonal antibody Vascular endothelial growth factor antagonist Half-life N/A... 

Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor, which prevents it from binding to its receptors, ultimately resulting in angiogenesis. 

The role of bevacizumab, a monoclonal antibody targeted against vascular endothelial growth factor, in MBC is currently not clearly defined. 

Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor. Bevacizumab is associated with hypertension, which is easily managed with oral antihypertensive agents. 

Bevacizumab, a recombinant, humanized monoclonal antibody, neutralizes vascular endothelial growth factor. The addition of bevacizumab to doublet chemotherapy is recommended in advanced NSCLC of nonsqua-mous cell histology in patients with no history of hemoptysis and no CNS metastasis who are not receiving therapeutic anticoagulation. 

Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor. It should be used with caution in patients with a history of hypertension because of an increased risk of proteinuria and in patients with uncontrolled hypertension. Side-effects that may be expected include... 

Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine kinase inhibitors. Cancer Metastasis Rev 1999 18 4734-81. 

S. K. Kelley, and A. Sandler. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-l/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer./. Clin. Oncol. 23 2544-2555. 

Margolin K, Gordon M, Holmgren E. Phase lb trial of intravenous recombinant humanised monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients advanced cancer Pharmacologic and long term results. J Clin Oncol 2001 19 851-859. 

Recombinant human monoclonal antibody binds to vascular endothelial growth factor... 

Because of the potential effects on safety and activity, it is necessary to minimize the aggregate content in the final formulation. In the formulation screen for the recombinant humanized monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF), a reversible self-association of the protein was observed,... 

Moore, J.M.R. Patapoff, T.W. Cromwell, M.E.M. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 1999, 38 (42), 13,960-13,967. 

---